NewsRoom Articles - Page 2 of 238

TuesdayAug 30, 2022 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces the Availability of a Broadcast titled, “The Power of Science to Stop a Killer”

Lexaria’s latest broadcast highlights the company’s progress in finding a potential solution for hypertension treatment while also pointing out why such a solution is much needed at this point Since the company began developing its patented DehydraTECH(TM) technology in 2014, it has made significant progress in its clinical studies, even as it currently focuses on human clinical research to evaluate the tolerability, safety, and efficacy of its solution for hypertension treatment Lexaria expressed its confidence in its proposed solution, noting that it will not only be a safer but also better-tolerated drug candidate, unlike current alternatives in the market whose…

FridayAug 26, 2022 11:15 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Drug Development Program and Recent FDA Confirmation Position It for Favorable Valuation

Lexaria is a global innovator of drug delivery platforms, including its patented DehydraTECH(TM) technology The company recently released information that would help its stakeholders research and understand how biotech and pharmaceutical companies are valued Based on some of the methodologies used in valuation, Lexaria is positioned favorably as its DehydraTECH-processed CBD for the treatment of hypertension has successfully reached the IND application stage, with the program recently receiving an additional boost The FDA agreed with Lexaria’s proposal to pursue a 505(b)(2) new drug application (“NDA”) regulatory pathway, an abbreviated pathway, for its hypertension program As a follow-up to recent coverage…

FridayAug 19, 2022 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Delighted About Well-Received DehydraTECH-CBD Proposals by the FDA; Maintains Late 2022/Early 2023 Target For Complete IND Application

Lexaria’s successful HYPER-H21-2 human clinical study, whose results were announced in the first week of September 2021, laid the groundwork for the company’s patented DehydraTECH(TM)-processed CBD NDA Chris Bunka, the company’s CEO, referred to the results as “statistically significant,” ultimately kickstarting the IND application process with the FDA Lexaria has since received a full written positive response from the FDA on its DehydraTECH-CBD, agreeing to the company’s proposal to pursue the 505(b)(2) NDA regulatory pathway As a result of the favorable FDA response, Lexaria expects to remain on track to file its full IND application, 6-9 months sooner than if…

TuesdayAug 16, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Enters Four Partnerships, Boosts ‘Revenue Picture’

Lexaria Bioscience, a global innovator in drug delivery platforms, recently announced partnerships with Premier Wellness Science Co., BevNology, AnodGen Bioceuticals, and Valcon Medical A/S According to coverage by Zacks Small-Cap Research, who value Lexaria at $15 per share, the most impactful of these partnerships is with Premier because the company is expected to start paying license fees in early September In a June 7 Fireside Chat, Lexaria Chair and CEO Chris Bunka disclosed that the company is capitalizing on partnerships with “national players in different areas of the world” to improve its “revenue picture” and offset its cash burn In…

FridayAug 12, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Inches Closer to DehydraTECH-CBD FDA Evaluation Following Successful Dosing in Multi-Week HYPER-H21-4 Human Clinical Study

Lexaria just completed dosing for its HYPER H21-4 human clinical study that dosed 64 patients aged between 40 and 70 with measured elevated blood pressure, stage 1 and stage 2 hypertension HYPER-H21-4, Lexaria’s most ambitious hypertension clinical study yet, builds on the success of HYPER-H21-1 and HYPER-H21-2, both completed in 2021 It explores the use of the company’s patented DehydraTECH(TM) technology in the potential treatment of hypertension Lexaria is confident that the additional data sets collected over the course of the study will lead to supplementary applications for DehydraTECH while providing valuable additional insights into the long-term health benefits of…

ThursdayAug 11, 2022 9:00 am

Advanced Container Technologies Inc. (ACTX) Establishing Foothold in Growing Billion-Dollar Vertical Farming Space

Vertical farming projected to reach more than $25 billion by 2030, with a CAGR of 23.3% MRFR report notes that “vertical farming systems and technologies offer a superior approach to farming methods” ACTX GrowPods are essentially vertical micro-farms that can be placed anywhere, allow cultivation of a wide variety of crops, 365 days a year A recent Market Research Future (“MRFR”) report shows that vertical farming is projected to reach more than $25 billion by 2030, with a CAGR of 23.3% (https://cnw.fm/kKdVm). Those numbers bode well for Advanced Container Technologies (OTC: ACTX), a company in the business of selling GrowPods,…

TuesdayAug 09, 2022 10:30 am

Advanced Container Technologies Inc. (ACTX) GrowPods May be Part of Solution to Global Food Security

In 2021, a staggering 45 million people were at emergency levels of acute hunger Providing access to food, sustainable food systems are key to WFP’s vision of eradicating food insecurity and malnutrition GrowPods create an optimum controlled environment for growing a wide range of crops in a variety of environments and climates With hunger on the rise again, companies and communities are working together to find realistic solutions. The world’s largest humanitarian organization, the World Food Programme (“WFP”), has identified access to food and sustainable food systems as two of eight key targets in its vision to eradicate food insecurity…

TuesdayAug 09, 2022 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces First Generation of CBD Products Under “Ko” Branding by Japanese Licensee Premier Wellness Science Co., Ltd.

Lexaria’s patented DehydraTECH(TM) has 26 granted patents worldwide, including four in Japan Lexaria stands to gain substantial revenue through the licensing of DehydraTECH technology across minimum quarterly payments for license use by Premier and royalties for products sold By 2028, the CBD market is expected to reach US$47.22 billion, driven by increased demand for CBD use in health and wellness Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms and developer of the patented DehydraTECH(TM) technology for the delivery of fat-soluble molecules and drugs, has announced that Japanese Licensee, Premier Wellness Science Co., Ltd., has officially launched the…

MondayJul 25, 2022 12:00 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Notice of Allowance of 26th Worldwide Patent

Lexaria, a global innovator in drug delivery technology, has developed the patented DehydraTECH(TM) technology which has been the subject of several issued patents Recently, Lexaria reported it had been notified of the allowance of its 26th worldwide patent with a new patent to be granted in Japan The patent is the fourth to be granted in Japan and the first patent issued from Lexaria’s seventh patent family Lexaria also submitted a briefing book to the FDA to facilitate its upcoming pre-Investigational New Drug (“IND”) meeting with the agency “We are extremely pleased to have received our first patent protecting our…

WednesdayJul 20, 2022 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Pending Start of Human Nicotine Study, NIC-H22-1, Leveraging Fast-Growing Global Nicotine Pouches Market

Lexaria Bioscience Corp. expects the upcoming human nicotine study to produce evidence that its patented DehydraTECH(TM) technology can enhance oral-tissue absorption with reduced negative experiences Data collected from animal study NIC-A21-1 showed that DehydraTECH enhanced oral nicotine pouches delivered peak nicotine levels in the bloodstream of animals 10x to 20x faster than the control The global nicotine pouches market was valued at $2.33 billion in 2020 and is expected to reach $21.84 billion by 2027, being one of the fastest growing segments in the nicotine industry Lexaria's pipeline addresses serious unmet patient or consumer needs with greater market potential, addressing…

News and publishing service for CBD related companies

Contact us: 303.498.7722